Norgine Announces EU Marketing Authorization for XOLREMDI® to Treat Rare WHIM Syndrome

Norgine Receives EU Approval for XOLREMDI® (Mavorixafor)

Norgine, a prominent European pharmaceutical company, has announced a groundbreaking development in the field of medical treatments. The European Commission has granted marketing authorization for XOLREMDI® (mavorixafor), making it the first approved treatment specifically for patients suffering from WHIM syndrome. This rare immunodeficiency disease has long been a challenge for those affected, and this approval marks a significant milestone in providing essential medical care.

A Historic Approval

The authorization from the European Commission came after a favorable opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The EU's decision is particularly noteworthy as it was granted under exceptional circumstances, reflecting the rarity of WHIM syndrome. The approval provides hope to individuals over the age of 12 suffering from this disease, as it is designed to increase the levels of neutrophils and mature lymphocytes in circulation.

Understanding WHIM Syndrome

WHIM syndrome, an acronym derived from its hallmark symptoms—warts, hypogammaglobulinemia, recurrent infections, and myelokathexis—is caused by a mutation affecting the CXCR4 receptor. This defect hampers the movement of white blood cells from the bone marrow into the bloodstream, leading to recurrent and severe infections for those afflicted. Prior to this authorization, patients had few, if any, effective treatment options available.

Commitment to Patients

Janneke van der Kamp, the CEO of Norgine, expressed the significance of this development: "The approval of XOLREMDI® in the European Union represents a monumental milestone for individuals living with WHIM syndrome, a condition that has historically lacked established treatment avenues. We are dedicated to delivering innovative medicines that meet critical unmet medical needs for patients across Europe, Australia, and New Zealand. Our collaboration with health authorities and the rare disease community aims to make mavorixafor accessible to those in need as swiftly as possible."

Clinical Trial Insights

The marketing authorization in Europe is founded on results from the pivotal Phase 3 WHIM trial, which was a globally conducted, randomized, double-blinded, placebo-controlled study. This extensive trial evaluated the efficacy and safety of mavorixafor in 31 individuals diagnosed with WHIM syndrome, showcasing promising results that helped propel the drug into the European market.

Community Reactions

Johan Prevot, CEO of the International Patient Organization for Primary Immunodeficiencies (IPOPI), remarked on the implications of this approval: "This landmark decision for the WHIM syndrome community in Europe is life-changing. For patients and families burdened with recurrent severe infections due to this rare primary immunodeficiency, the facilitation of an authorized treatment signifies a crucial advancement. We will continue advocating for patient voices throughout Europe and beyond to ensure that national health systems recognize the value of innovative treatments and provide equitable access to patients, regardless of their geographical location."

Collaboration for Future Success

In January 2025, Norgine and X4 Pharmaceuticals entered a licensing and supply agreement that allows Norgine to market mavorixafor in Europe, Australia, and New Zealand following regulatory approval. Once the authorization process is complete, Norgine will oversee all market access and promotional activities in the specified regions, while X4 will handle the manufacturing and supply of mavorixafor.

Conclusion: A New Era for WHIM Syndrome Management

WHIM syndrome poses unique challenges due to its rare nature and the complex medical needs that arise from it. Mavorixafor, as a selective CXCR4 antagonist, binds to the CXCR4 receptor, inhibiting its interaction with CXCL12—thus potentially transforming how this condition is managed. Norgine’s commitment to innovation and meeting the needs of patients underscores its mission, which is dedicated to advancing healthcare in Europe and beyond.

In providing new hope through XOLREMDI®, Norgine reaffirms its focus on delivering transformative medical solutions that can enhance the lives of patients challenged by rare and significant health issues.